AGING CELL:人类细胞中的α-突触核蛋白毒性是如何引起的?

2019-04-12 海北 MedSci原创

α-突触核蛋白(aSyn)毒性与细胞周期改变,DNA损伤反应的激活(DDR)和自噬的失调有关。然而,至今为止,这些现象之间的关系仍然很大程度上未知。

α-突触核蛋白(aSyn)毒性与细胞周期改变,DNA损伤反应的激活(DDR)和自噬的失调有关。然而,至今为止,这些现象之间的关系仍然很大程度上未知。

最近,研究人员证明,在aSyn毒性和衰老的酵母模型中,aSyn表达诱导Ras2依赖性生长信号传导,细胞周期的重新进入,DDR激活,自噬和核糖核苷酸还原酶1(Rnr1)的自噬降解,这是一种核糖核苷酸还原酶和dNTP合成的活性必须的蛋白质。这些事件导致细胞死亡和衰老。通过删除RAS2,抑制DDR或自噬,或过表达RNR1可以消除这些事件。

人H4神经胶质瘤细胞中的aSyn表达也诱导细胞周期再进入和S期阻滞,自噬和RRM1(RNR1的人类同源物)的降解。此外,抑制RRM1的自噬降解可以从细胞死亡中拯救细胞。

该研究结果代表了一种毒性的模型,对于了解突触核蛋白病,以及其他与年龄相关的神经退行性疾病具有重要意义。


原始出处:

Belém Sampaio‐Marque et al. α‐Synuclein toxicity in yeast and human cells is caused by cell cycle re‐entry and autophagy degradation of ribonucleotide reductase 1. AGING CELL, 2019; doi:  https://doi.org/10.1111/acel.12922


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1871216, encodeId=8d2a18e121655, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Sep 07 23:18:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986088, encodeId=493619860886c, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Feb 04 13:18:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961496, encodeId=8e4e196149681, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 26 21:18:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478790, encodeId=38f314e8790d7, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Sun Apr 14 11:18:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524518, encodeId=f2e81524518f7, content=<a href='/topic/show?id=f077191350d' target=_blank style='color:#2F92EE;'>#α-突触核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19135, encryptionId=f077191350d, topicName=α-突触核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Apr 14 11:18:00 CST 2019, time=2019-04-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1871216, encodeId=8d2a18e121655, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Sep 07 23:18:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986088, encodeId=493619860886c, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Feb 04 13:18:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961496, encodeId=8e4e196149681, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 26 21:18:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478790, encodeId=38f314e8790d7, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Sun Apr 14 11:18:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524518, encodeId=f2e81524518f7, content=<a href='/topic/show?id=f077191350d' target=_blank style='color:#2F92EE;'>#α-突触核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19135, encryptionId=f077191350d, topicName=α-突触核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Apr 14 11:18:00 CST 2019, time=2019-04-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1871216, encodeId=8d2a18e121655, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Sep 07 23:18:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986088, encodeId=493619860886c, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Feb 04 13:18:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961496, encodeId=8e4e196149681, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 26 21:18:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478790, encodeId=38f314e8790d7, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Sun Apr 14 11:18:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524518, encodeId=f2e81524518f7, content=<a href='/topic/show?id=f077191350d' target=_blank style='color:#2F92EE;'>#α-突触核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19135, encryptionId=f077191350d, topicName=α-突触核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Apr 14 11:18:00 CST 2019, time=2019-04-14, status=1, ipAttribution=)]
    2020-02-26 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1871216, encodeId=8d2a18e121655, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Sep 07 23:18:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986088, encodeId=493619860886c, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Feb 04 13:18:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961496, encodeId=8e4e196149681, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 26 21:18:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478790, encodeId=38f314e8790d7, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Sun Apr 14 11:18:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524518, encodeId=f2e81524518f7, content=<a href='/topic/show?id=f077191350d' target=_blank style='color:#2F92EE;'>#α-突触核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19135, encryptionId=f077191350d, topicName=α-突触核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Apr 14 11:18:00 CST 2019, time=2019-04-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1871216, encodeId=8d2a18e121655, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Sep 07 23:18:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986088, encodeId=493619860886c, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Feb 04 13:18:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961496, encodeId=8e4e196149681, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 26 21:18:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478790, encodeId=38f314e8790d7, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Sun Apr 14 11:18:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524518, encodeId=f2e81524518f7, content=<a href='/topic/show?id=f077191350d' target=_blank style='color:#2F92EE;'>#α-突触核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19135, encryptionId=f077191350d, topicName=α-突触核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Apr 14 11:18:00 CST 2019, time=2019-04-14, status=1, ipAttribution=)]

相关资讯

Neurosci Lett:如此神奇!地中海植物提取物或可有效抵御多种神经变性疾病

图片来源:www.sciencedaily.com 阿尔兹海默病和帕金森疾病是两种和年龄相关相关的神经变性疾病,其主要特点就是随着时间延续,患者的大脑中会积累损伤患者机体神经系统的粘性蛋白聚集物,进而就会影响患者的运动能力和记忆力。日前一项发表在国际杂志Neuroscience Letters上的研究报告中,来自马尔他大学等机构的研究人员通过研究发现,提取自地中海植物仙人掌和褐海藻中的特

Sci Rep:突破!利用CRISPR-Cas9技术开发出帕金森疾病新型筛选工具

近日,一项发表在国际杂志Scientific Reports上的研究报告中,来自中佛罗里达大学(University of Central Florida)的研究人员通过研究利用突破性的基因编辑技术开发出了一种帕金森疾病的新型筛查工具,帕金森疾病是一种严重的神经系统疾病,这种技术能够帮助科学家们在实验室中对名为α-突触核蛋白的大脑蛋白进行实

Science:重磅!帕金森症关键毒性物质被找到!

帕金森病是一种神经退行性疾病。帕金森症患者的生活质量一直很低。而在近期的《Science》期刊上面,一篇新的研究揭示了帕金森症背后的关键毒性物质!

JAMA Neurol:α-突触核蛋白单抗PRX002 I期临床结果喜人

研究认为,PRX002治疗具有极高的耐受性,与外周α-突触核蛋白结合率高。脑脊液药物浓度高于外周,可结合脑细胞外聚集α-突触核蛋白达到预期的治疗效果

PLoS One:通过外泌体分泌载体膜蛋白5促进α-突触核蛋白的分泌

自噬溶酶体途径是一种清除聚集蛋白和受损细胞器的细胞保护系统。同时,外泌体分泌是一种选择性的清除毒性蛋白的模式,如α-突触核蛋白。越来越多的证据表明,这两种细胞过程是协调的,以便于清除有毒的细胞废物;然而,这两种过程之间转换的调节器目前尚不清楚。本研究中,研究人员发现,SCAMP5——亨廷顿病患者的大脑中明显增多的一种分泌载体膜蛋白,可被蛋白压力和自噬刺激快速而短暂的诱导,是由主自噬转录调节因子TF

Sci Trans Med:帕金森治疗新策略,有望2022年临床试验

帕金森(PD)是一种发病率仅次于阿尔兹海默症的神经衰退性疾病,是威胁中老年人健康和生命的“第三杀手”。近日,《Science Translational Medicine》期刊发表一项最新研究揭示了一种小分子,有望阻止PD进展。